Skip to main content

Advertisement

SpringerLink
Log in

Curability risks by endoscopic submucosal dissection for early gastric cancer

  • Letter
  • Published:
Surgical Endoscopy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ohnita K, Isomoto H, Yamaguchi N, Fukuda E, Nakamura T, Nishiyama H, Mizuta Y, Akiyama M, Nakao K, Kohno S, Shikuwa S (2009) Factors related to the curability of early gastric cancer with endoscopic submucosal dissection. Surg Endosc Apr 9. [Epub ahead of print]

  2. Yokota T, Ishiyama S, Saito T, Teshima S, Shimotsuma M, Yamauchi H (2003) Treatment strategy of limited surgery in the treatment guidelines for gastric cancer in Japan. Lancet Oncol 4(7):423–428

    Article  PubMed  Google Scholar 

  3. Kang HY, Kim SG, Kim JS, Jung HC, Song IS (2009) Clinical outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. Surg Endosc Jul 8. [Epub ahead of print]

  4. Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125

    Article  CAS  PubMed  Google Scholar 

  5. Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651

    Article  Google Scholar 

  6. Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9(9):828–830

    Article  PubMed  Google Scholar 

  7. Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798

    Article  PubMed  Google Scholar 

  8. Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696

    Article  PubMed  Google Scholar 

  9. Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726

    Article  CAS  PubMed  Google Scholar 

  10. Briasoulis E, Fatouros M et al (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695

    Article  PubMed  Google Scholar 

  11. Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406

    Article  Google Scholar 

  12. Briasoulis E, Liakakos T, Dova L et al (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939

    Article  PubMed  Google Scholar 

  13. Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350

    Article  Google Scholar 

  14. Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555

    Article  CAS  PubMed  Google Scholar 

  15. Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068

    Article  PubMed  Google Scholar 

  16. Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782

    Article  PubMed  Google Scholar 

  17. Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338

    Article  PubMed  Google Scholar 

  18. Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362–1363

    Article  CAS  PubMed  Google Scholar 

  19. Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8(5):587–597

    Article  PubMed  Google Scholar 

  20. Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361

    Article  PubMed  Google Scholar 

  21. Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16(3):774–775

    Article  PubMed  Google Scholar 

  22. Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636

    CAS  PubMed  Google Scholar 

  23. Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141

    Article  PubMed  Google Scholar 

  24. Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6

    Article  CAS  PubMed  Google Scholar 

  25. Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715

    Article  PubMed  Google Scholar 

  26. Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773

    Article  PubMed  Google Scholar 

  27. Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229

    Article  PubMed  Google Scholar 

  28. Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221

    Article  PubMed  Google Scholar 

  29. Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392

    Article  PubMed  Google Scholar 

  30. Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416

    Article  PubMed  Google Scholar 

  31. Roukos DH (2009) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol. doi:10.1245/s10434-009-0766-0

  32. Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681

    Article  PubMed  Google Scholar 

Download references

Disclosures

Prof. Christof Hottenrott has no conflicts of interest or financial ties to disclose.

Author information

Authors and Affiliations

  1. Chirurgische Klinik St. Elisabethenkrankenhaus Ginnheimer Straße 3, Frankfurt, 60487, Germany

    Christof Hottenrott

Authors
  1. Christof Hottenrott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christof Hottenrott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hottenrott, C. Curability risks by endoscopic submucosal dissection for early gastric cancer. Surg Endosc 24, 1224–1225 (2010). https://doi.org/10.1007/s00464-009-0749-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00464-009-0749-z

Keywords

Search

Navigation